Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia
Z Li, Y Qiao, B Liu, EJ Laska, P Chakravarthi… - Clinical Cancer …, 2005 - AACR
Purpose: To test the feasibility, safety, immunogenicity, and clinical efficacy of an autologous
vaccine of leukocyte-derived heat shock protein 70-peptide complexes (Hsp70PC), in …
vaccine of leukocyte-derived heat shock protein 70-peptide complexes (Hsp70PC), in …
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate
BD Smith, YL Kasamon, J Kowalski, C Gocke… - Clinical Cancer …, 2010 - AACR
Purpose: Chronic myeloid leukemia (CML) can be responsive to T-cell–mediated immunity.
K562/granulocyte macrophage-colony stimulating factor (GM-CSF) is a GM-CSF producing …
K562/granulocyte macrophage-colony stimulating factor (GM-CSF) is a GM-CSF producing …
Imatinib mesylate effectively combines with chaperone‐rich cell lysate‐loaded dendritic cells to treat bcr‐abl+ murine leukemia
Y Zeng, MW Graner, H Feng, G Li… - International journal of …, 2004 - Wiley Online Library
Imatinib mesylate has become an effective agent for the treatment of chronic myeloid
leukemia (CML). However, the development of drug resistance has led to examination of …
leukemia (CML). However, the development of drug resistance has led to examination of …
[HTML][HTML] Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy
The ability to target myeloid leukemia with immunotherapy would represent a significant
therapeutic advance. We report here immunological analysis of clinical trials of primary and …
therapeutic advance. We report here immunological analysis of clinical trials of primary and …
Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia
M Pocaly, V Lagarde, G Etienne, JA Ribeil, S Claverol… - Leukemia, 2007 - nature.com
Imatinib is an effective therapy for chronic myeloid leukemia (CML), a myeloproliferative
disorder characterized by the expression of the recombinant oncoprotein Bcr-Abl. In this …
disorder characterized by the expression of the recombinant oncoprotein Bcr-Abl. In this …
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre …
M Bocchia, S Gentili, E Abruzzese, A Fanelli, F Iuliano… - The Lancet, 2005 - thelancet.com
Background Although imatinib is the standard treatment for chronic myeloid leukaemia, not
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …
[HTML][HTML] Antigens in chronic myeloid leukemia: implications for vaccine development
M Šmahel - Cancer Immunology, Immunotherapy, 2011 - Springer
Abstract Treatment with imatinib mesylate and other tyrosine kinase inhibitors (TKI)
revolutionized the therapy of chronic myeloid leukemia (CML). However, it alone does not …
revolutionized the therapy of chronic myeloid leukemia (CML). However, it alone does not …
BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells
KM Brauer, D Werth, K von Schwarzenberg… - Cancer research, 2007 - AACR
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder caused by excessive
granulopoiesis due to the formation of the constitutively active tyrosine kinase BCR-ABL. An …
granulopoiesis due to the formation of the constitutively active tyrosine kinase BCR-ABL. An …
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I–induced leukemia and suppresses leukemic stem cells
C Peng, J Brain, Y Hu, A Goodrich… - Blood, The Journal …, 2007 - ashpublications.org
Abstract Development of kinase domain mutations is a major drug-resistance mechanism for
tyrosine kinase inhibitors (TKIs) in cancer therapy. A particularly challenging example is …
tyrosine kinase inhibitors (TKIs) in cancer therapy. A particularly challenging example is …
Synthetic tumor‐specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial
N Jain, JM Reuben, H Kantarjian, C Li… - … Journal of the …, 2009 - Wiley Online Library
BACKGROUND: Imatinib is the current standard frontline therapy for chronic myelogenous
leukemia (CML). In the majority of patients, imatinib induces a complete cytogenetic …
leukemia (CML). In the majority of patients, imatinib induces a complete cytogenetic …